H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 123 Citations 50,877 1,302 World Ranking 1352 National Ranking 818

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Internal medicine, Leukemia, Gastroenterology, Surgery and Myeloid leukemia are his primary areas of study. His Internal medicine research integrates issues from Immunology and Oncology. His work in Oncology addresses subjects such as Survival analysis, which are connected to disciplines such as Salvage therapy.

He has researched Leukemia in several fields, including Myeloid and Pharmacology. His work deals with themes such as Cytarabine, Phases of clinical research, Blastic Phase and Survival rate, which intersect with Gastroenterology. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Mutation, Fms-Like Tyrosine Kinase 3 and Young adult.

His most cited work include:

  • New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge (440 citations)
  • Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents (380 citations)
  • Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes (329 citations)

What are the main themes of his work throughout his whole career to date?

Guillermo Garcia-Manero mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Myelodysplastic syndromes. His Internal medicine research is multidisciplinary, incorporating perspectives in Surgery and Decitabine. Guillermo Garcia-Manero has included themes like Azacitidine, Cancer, Immunology and Transplantation in his Oncology study.

His work carried out in the field of Myeloid leukemia brings together such families of science as Tyrosine kinase and Bone marrow. The study incorporates disciplines such as Refractory, Imatinib mesylate, Vincristine, Adverse effect and Neutropenia in addition to Gastroenterology. The various areas that Guillermo Garcia-Manero examines in his Leukemia study include Myeloid and Pharmacology.

He most often published in these fields:

  • Internal medicine (73.03%)
  • Oncology (37.10%)
  • Myeloid leukemia (25.74%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (73.03%)
  • Oncology (37.10%)
  • Myeloid leukemia (25.74%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Azacitidine. His studies in Oncology integrate themes in fields like Cytarabine, Decitabine, Venetoclax, Blinatumomab and Transplantation.

The Myeloid leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Chemotherapy regimen, Myeloid, Bone marrow and Cohort. His Myelodysplastic syndromes research includes elements of Lower risk, Clinical trial and Anemia. His research is interdisciplinary, bridging the disciplines of Cancer and Leukemia.

Between 2018 and 2021, his most popular works were:

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (140 citations)
  • The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (82 citations)
  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (64 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Hui Yang;Carlos Bueso-Ramos;Courtney DiNardo;Marcos R Estecio.
Leukemia (2014)

577 Citations

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva.
Cancer (2010)

478 Citations

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Rafael Bejar;Kristen E. Stevenson;Bennett A. Caughey;Omar Abdel-Wahab.
Journal of Clinical Oncology (2012)

457 Citations

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo.
Journal of Clinical Oncology (2012)

440 Citations

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

Hagop M. Kantarjian;Moshe Talpaz;Susan O'Brien;Francis Giles.
Blood (2003)

435 Citations

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Elihu Estey;Guillermo Garcia-Manero;Alessandra Ferrajoli;Stefan Faderl.
Blood (2006)

429 Citations

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

Farhad Ravandi;Jorge E. Cortes;Daniel Jones;Stefan Faderl.
Journal of Clinical Oncology (2010)

427 Citations

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Hagop M. Kantarjian;Jorge Cortes;Susan O'Brien;Susan O'Brien;Francis J. Giles;Francis J. Giles.
Blood (2002)

421 Citations

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

Hagop M Kantarjian;Varsha Gandhi;Jorge Cortes;Srdan Verstovsek.
Blood (2003)

418 Citations

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero.
Journal of Clinical Oncology (2010)

403 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Guillermo Garcia-Manero

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 557

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 425

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 237

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 200

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 178

Pierre Fenaux

Pierre Fenaux

Université Paris Cité

Publications: 149

Elihu H. Estey

Elihu H. Estey

Fred Hutchinson Cancer Research Center

Publications: 139

Srdan Verstovsek

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center

Publications: 135

Mikkael A. Sekeres

Mikkael A. Sekeres

Cleveland Clinic

Publications: 131

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 126

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 125

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 124

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 121

Martin S. Tallman

Martin S. Tallman

Memorial Sloan Kettering Cancer Center

Publications: 115

Mark R. Litzow

Mark R. Litzow

Mayo Clinic

Publications: 113

Marina Konopleva

Marina Konopleva

The University of Texas MD Anderson Cancer Center

Publications: 110

Something went wrong. Please try again later.